Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study
Therapeutic Advances in Medical Oncology · 2026-08 · 18
DOI: 10.1177/17588359261470598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 20.08.2026. Verfasst von Davide Bimbatti und 40 weiteren Autor:innen. Beteiligte Einrichtung: Oncology 1 Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Italian Ministry of Health–Ricerca Corrente.
Abstract (Originalsprache)
Background
Despite the availability of several first-line (1L) systemic therapies for metastatic renal cell carcinoma (mRCC), no validated biomarkers currently guide the selection of 1L systemic treatment.
Objectives
To identify baseline clinical features associated with 1L treatment selection in a large real-world mRCC population.
Design
Meet-URO 33–REGAL is a multicenter study with prospective and retrospective components, enrolling patients with mRCC receiving 1L systemic therapy since January 2021.
Methods
Baseline patient and disease characteristics were analyzed to compare treatment selection among dual immune checkpoint inhibitor therapy (ICI–ICI), ICI plus tyrosine kinase inhibitor combinations (ICI–TKI), and TKI monotherapy. Multivariable logistic regression models were used to evaluate clinical features associated with pairwise treatment selection.
Results
A total of 1695 patients from 58 centers were included: 248 (14.6%) received TKI monotherapy, 338 (20.0%) ICI–ICI, and 1109 (65.4%) ICI–TKI. ICI–ICI was more commonly selected in patients with sarcomatoid features (14.5% vs 7.4% for ICI–TKI, p < 0.001) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate/poor-risk disease (92.0% vs 80.1%, p < 0.001). In multivariable analysis, compared with TKI monotherapy, ICI–TKI selection was associated with IMDC intermediate-risk disease (odds ratio (OR) 2.16, 95% confidence interval (CI) 1.25–3.74, p = 0.006), poor-risk disease (OR 2.89, 95% CI 1.38–6.06, p = 0.005), and bone metastases (OR 1.79, 95% CI 1.29–2.49, p = 0.001). In regimen-specific comparisons, nivolumab plus cabozantinib was associated with bone metastases and non-clear cell histology; pembrolizumab plus lenvatinib with eastern cooperative oncology group (ECOG) performance status 0 and pancreatic involvement; and nivolumab plus ipilimumab with cardiovascular and metabolic comorbidities and lymph node metastases. TKI monotherapy was more commonly selected in older patients and those with comorbidities, consistent with a more selected clinical phenotype in routine clinical practice.
Conclusion
Meet-URO 33 provides a real-world snapshot of 1L decision-making in mRCC. Distinct clinical patterns, including histology, metastatic sites, performance status, comorbidities, and prognostic risk, were associated with treatment selection. These findings characterize clinical phenotypes in routine practice and provide context for future effectiveness, safety, and treatment-sequencing analyses of 1L therapeutic strategies within the Meet-URO 33 cohort over time.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oncology 1 Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
- Medical Oncology, Ospedale Santa Corona, Pietra Ligure, Italy.
- University of Turin, A.O.U. Città della Salute e della Scienza di Torino, Ospedale Molinette, Turin, Italy.
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
- Medicine and Surgery Department, University of Parma, Parma, Italy.
- Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
ORCID-Profile: Brigida Anna Maiorano, Alessia Cavo, Vincenza Conteduca, Fabrizio Di Costanzo, Sara Elena Rebuzzi
Förderung
- Italian Ministry of Health–Ricerca Corrente
Zitieren
APA
Bimbatti, D., Nasso, C., Aspden, D., Buti, S., Antonj, L., Signori, A., Verzoni, E., Lolli, C., Di Napoli, M., Fanelli, M., De Lucia, M., Masini, C., Roviello, G., Arduini, D., Filippi, R., Mennitto, A., Sorarù, M., Bozza, G., Formisano, L., …, & Rebuzzi, S. E. (2026). Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261470598
Vancouver
Bimbatti D, Nasso C, Aspden D, Buti S, Antonj L, Signori A, et al. Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261470598
BibTeX
@article{Bimbatti2026,
author = {Bimbatti, Davide and Nasso, Cecilia and Aspden, Domiziana and Buti, Sebastiano and Antonj, Ludovica and Signori, Alessio and Verzoni, Elena and Lolli, Cristian and Di Napoli, Marilena and Fanelli, Martina and De Lucia, Miriam and Masini, Cristina and Roviello, Giandomenico and Arduini, Daniela and Filippi, Roberto and Mennitto, Alessia and Sorarù, Mariella and Bozza, Giovanni and Formisano, Luigi and Messina, Carlo and Bonomi, Lucia and Guida, Annalisa and Fantinel, Emanuela and Scagliarini, Sarah and Vitale, Maria Giuseppa and Chiellino, Silvia and Maiorano, Brigida Anna and Deppieri, Filippo Maria and Zucali, Paolo Andrea and Cavo, Alessia and Caserta, Claudia and La Russa, Francesca and Conteduca, Vincenza and Maines, Francesca and Zai, Silvia and Pierantoni, Francesco and Icardi, Massimiliano and Rescigno, Pasquale and Di Costanzo, Fabrizio and Banna, Giuseppe Luigi and Rebuzzi, Sara Elena},
title = {Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261470598}
}
EUVIMED